The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants
- PMID: 21564455
- PMCID: PMC3315186
- DOI: 10.1111/j.1399-5448.2011.00774.x
The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants
Abstract
Aims: The Environmental Determinants of Diabetes in the Young (TEDDY) study seeks to identify environmental factors influencing the development of type 1 diabetes (T1D) using intensive follow-up of children at elevated genetic risk. This study requires a cost-effective yet accurate screening strategy to identify the high-risk cohort.
Methods: The TEDDY cohort was identified through newborn screening using human leukocyte antigen (HLA) class II genes based on criteria established with pre-TEDDY data. HLA typing was completed at six international centers using different genotyping methods that can achieve >98% accuracy.
Results: TEDDY developed separate inclusion criteria for the general population (GP) and first-degree relatives (FDRs) of T1D patients. The FDR eligibility includes nine haplogenotypes (DR3/4, DR4/4, DR4/8, DR3/3, DR4/4b, DR4/1, DR4/13, DR4/9, and DR3/9) for broad HLA diversity, whereas the GP eligibility includes only the first four haplogenotypes with DRB1*0403 as an exclusion allele. TEDDY has screened 414 714 GP infants, of which 19 906 (4.8%) were eligible, whereas 1415 of the 6333 screened FDR infants (22.2%) were eligible. High-resolution confirmation testing of the eligible subjects indicated that the low-cost and low-resolution genotyping techniques employed at the screening centers yielded an accuracy of 99%. There were considerable variations in eligibility rates among the centers for GP (3.5-7.4%) and FDR (19-32%) subjects. The eligibility rates among US ethnic groups were 0.9, 1.3, 5.0, and 6.9% for Asians, Black, Caucasians, and Hispanics, respectively.
Conclusions: Different low-cost and low-resolution genotyping methods are useful for the efficient and accurate identification of a high-risk cohort for follow-up based on the TEDDY HLA inclusion criteria.
Trial registration: ClinicalTrials.gov NCT00279318.
© 2011 John Wiley & Sons A/S.
References
-
- She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today. 1996;17:323–329. - PubMed
-
- Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet. 2006;38:617–619. - PubMed
-
- Hakonarson H, Grant SFA, Bradfield JP, et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature. 2007;448:591–594. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U01 DK063821/DK/NIDDK NIH HHS/United States
- DK 63865/DK/NIDDK NIH HHS/United States
- DK 63821/DK/NIDDK NIH HHS/United States
- UC4 DK063821/DK/NIDDK NIH HHS/United States
- HHSN267200700014C/DK/NIDDK NIH HHS/United States
- U01 DK063861/DK/NIDDK NIH HHS/United States
- DK 63790/DK/NIDDK NIH HHS/United States
- DK 63861/DK/NIDDK NIH HHS/United States
- DK 63863/DK/NIDDK NIH HHS/United States
- U01 DK063829/DK/NIDDK NIH HHS/United States
- U01 DK063865/DK/NIDDK NIH HHS/United States
- UC4 DK095300/DK/NIDDK NIH HHS/United States
- DK 63829/DK/NIDDK NIH HHS/United States
- UC4 DK063861/DK/NIDDK NIH HHS/United States
- UC4 DK063829/DK/NIDDK NIH HHS/United States
- UC4 DK063865/DK/NIDDK NIH HHS/United States
- U01 DK063863/DK/NIDDK NIH HHS/United States
- DK 63836/DK/NIDDK NIH HHS/United States
- U01 DK063790/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
